AMPH — Amphastar Pharmaceuticals Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapContrarian

Annual cashflow statement for Amphastar Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	63.3	91.4	138	160	98.1
Depreciation
Amortisation
Deferred Taxes
Non-Cash Items	10.7	21.2	44.7	33.3	38.6
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-1.92	-32.2	-24.2	-14.5	-66
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Accrued Expenses
Change in Payable / Accrued Expenses
Change in Taxes Payable
Cash from Operating Activities	98	89.2	184	213	156
Capital Expenditures	-27.5	-24	-38.2	-41	-37.1
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-1.22	-8.74	-611	-83.9	-33.2
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Cash from Investing Activities	-28.7	-32.8	-649	-125	-70.3
Financing Cash Flow Items	-56.2	-0.407	-25.1	-0.816	-0.687
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-37	-26.4	454	-81	-67.4
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	32.1	29.7	-11.8	7.31	18.6